{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-087369","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.734090+00:00","generated_at":"2026-05-19T04:14:49.434894+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cardiff Oncology appoints Dr. Roger Sidhu as CMO; to share CRDF-004 data on July 29","bullets":["Dr. Fairooz Kabbinavar stepped down as CMO effective June 13, 2025; will remain as advisor.","Dr. Roger Sidhu appointed CMO; previously at Amgen, Treadwell Therapeutics, Roivant Sciences.","Sidhu receives $515K base salary, 45% target bonus, and option for 600K shares at $3.86 vesting over 4 years.","Company to report additional clinical data from Phase 2 CRDF-004 trial in RAS-mutated mCRC on July 29, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-087369","json":"https://secwatch.observer/filing/0000950170-25-087369.json","markdown":"https://secwatch.observer/filing/0000950170-25-087369.md","text":"https://secwatch.observer/filing/0000950170-25-087369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000095017025087369/0000950170-25-087369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000095017025087369/crdf-20250613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:14:49.434894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41eab03429","claim":"Dr. Fairooz Kabbinavar departed as Chief Medical Officer at Cardiff Oncology, Inc..","evidence_excerpt":"On June 13, 2025, Dr. Fairooz Kabbinavar and Cardiff Oncology, Inc. (the “Company”) agreed that he would be stepping down from his position as Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000095017025087369/0000950170-25-087369-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"4a9ace8998","claim":"Dr. Roger Sidhu was appointed as Chief Medical Officer at Cardiff Oncology, Inc..","evidence_excerpt":"On June 17, 2025, the Company announced that it has appointed Dr. Roger Sidhu as its new Chief Medical Officer and entered into an employment agreement with Dr. Sidhu on June 16, 2025 (the “Sidhu Employment Agreement”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000095017025087369/0000950170-25-087369-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}